Presentation is loading. Please wait.

Presentation is loading. Please wait.

Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by.

Published byChristopher Ly Modified over 9 years ago

Similar presentations

Presentation on theme: "Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by."— Presentation transcript:

1 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. SYMPLICITY HTN-3 Trial: 12-month outcomes following un-blinding of subjects at 6 months Overview of Presentations given by: Dr. George Bakris at ESC 2014 & Deepak Bhatt at TCT 2014

2 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. Background SYMPLICITY HTN-3 is the first randomized, blinded, sham-controlled clinical trial of renal denervation for treatment-resistant hypertension. Initial results confirmed the safety of renal denervation but did not achieve the 6-month primary efficacy endpoint.

3 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. 6-Month Primary Efficacy Endpoint *P value for superiority with a 5 mm Hg margin bars denote standard deviations

4 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. We now present the 12 month data of available patients Home BP & HTN med confirmation Office SBP ≥160 mm Hg Full doses ≥3 meds No med changes in past 2 weeks No planned med changes for 6 mo Screening Visit 1 Home BP & HTN med confirmation Home BP & HTN med confirmation Primary endpoint 2 weeks 1M 3M 6M6M 6M 12 -60M Patients, BP assessors, and study personnel all blinded to treatment status No changes in medications for 6 months 2 weeks Renal angiogram; Eligible subjects randomized Sham Procedure Renal Denervation Office SBP ≥160 mm Hg 24-h ABPM SBP ≥135 mm Hg Documented med adherence Screening Visit 2 Cross- over 2:1 randomization, blinded and sham controlled 535 subjects randomized out of 1441 enrolled at 88 sites in US Trial Design Bhatt DL, Kandzari DE, et al...Bakris GL N Engl J Med. 2014;370:1393-401.

5 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. Methods All clinicians and subjects were un-blinded to randomization following the primary 6-month endpoint evaluation. Sham control subjects were allowed to cross over to RDN following the 6-month primary endpoint evaluation if they continued to satisfy study inclusion and exclusion criteria. Follow up of the study cohort will continue for up to 5 years.

6 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. Patient Disposition: 6 Months to 1 Year 322 Subjects (91%) 12M follow-up 4 died 3 withdrew 354 eligible for 12M follow-up Crossover 101 Subjects Non-Crossover 70 Subjects 2 died 6 withdrew 2 died 3 withdrew 96 eligible for 6M post-RDN follow-up 93 Subjects (96.9%) 6M post-RDN follow-up Sham-Control group 171 Subjects Denervation group 361 Subjects 62 eligible for 12M follow-up 48 Subjects (77%) 12M follow-up Crossover subjects were denervated after unblinding at 6 months if blood pressure criteria for treatment were met and subjects elected to proceed.

7 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. Baseline Population Demographics Denervation n=364 Crossover n=101 Non-Crossover n=70 Age (years)58 ± 1055 ± 1158 ± 12 Male sex (%)59.162.467.1 Office systolic blood pressure (mm Hg)180 ± 16184 ± 19176 ± 15 24-hour mean systolic ABPM (mm Hg)159 ± 13163 ± 16155 ± 15 BMI (kg/m 2 )34.2 ± 6.533.0 ± 5.135.2 ± 7.8 Race (%) White73.071.367.1 Black or African American24.827.731.4 Medical history (%) Renal insufficiency (eGFR <60ml/min/1.73m 2 )9.69.910.0 Renal artery stenosis1.42.02.9 Obstructive sleep apnea25.837.622.9 Stroke8.211.910.0 Type 2 diabetes47.037.645.7 Hypertensive crisis23.120.824.3 Hyperlipidemia69.563.467.1 Current smoking9.914.98.6 Prescribed anti-hypertensive drugs >10 years68.172.362.9

8 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. Prescribed Antihypertensive Medications Denervation n=364 Crossover n=101 Non-Crossover n=70 Baseline5.1 ± 1.45.2 ± 1.65.2 ± 1.4 6 months5.0 ± 1.45.2 ± 1.65.1 ± 1.6 12 months5.0 ± 1.6n/a4.9 ± 1.5

9 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. Safety to 12 Months Denervation n=364 Crossover* n=101 Non-Crossover n=70 To 6 Months Composite Safety to 6M (%) 3.6 (13/358)5.2 (5/96)2.9 (2/70) Death0.62.11.4 New-onset end-stage renal disease0.0 Sig. embolic event resulting in end-organ damage0.30.0 Vascular complication0.30.0 Renal artery re-intervention0.0 Hypertensive crisis/emergency2.53.11.4 New renal artery stenosis >70%0.0 To 12 Months Composite Safety to 12M (%) 6.8 (24/355)n/a7.2 (5/69) Death1.8n/a3.6 New-onset end-stage renal disease0.3n/a0.0 Sig. embolic event resulting in end-organ damage0.3n/a0.0 Vascular complication0.3n/a0.0 Renal artery re-intervention0.6n/a0.0 Hypertensive crisis/emergency4.8n/a5.5 *Safety from time of crossover procedure

10 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. Procedural Details Denervation n=364 Crossover n=101 Non-Crossover n=70 Procedure time (min)93 ± 3876 ± 3056 ± 33 Denervation time (min)46 ± 1543 ± 12n/a Contrast volume (ml)177 ± 77138 ± 6081 ± 50 Treatment attempts11.2 ± 2.811.2 ± 2.4n/a Full 120-second treatments9.2 ± 2.09.4 ± 1.9n/a Hospital stay (days)1.0 ± 0.31.0 ± 0.11.1 ± 0.6

11 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. Medication Changes to 12 Months

12 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. Change in Office Blood Pressure through 12- Months Post-Procedure Baseline SBP (mm Hg)180179184* Baseline DBP (mm Hg)9795102* Note: BP changes are vs. patient baseline, not RDN – Control *Baseline = time of RDN procedure P=0.025 for SBP difference

13 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. Change in Office Blood Pressure through 12- Months Post-Procedure Baseline SBP (mm Hg)176 Baseline DBP (mm Hg)94 Note: BP changes are vs. patient baseline, not RDN – Control

14 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. Change in 24-h Ambulatory Blood Pressure at 6 and 12 Months for Denervation Subjects *Baseline = time of RDN procedure Note: BP changes are vs. patient baseline, not RDN vs Control. Error Bars = 1.96SE 158 95 163 94 Baseline SBP (mm Hg) Baseline DBP (mm Hg)

15 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. Note: BP changes are vs. patient baseline, not RDN – Control Baseline SBP (mm Hg)151 Baseline DBP (mm Hg)86 Change in 24-h Ambulatory Blood Pressure at 6 and 12 Months for Non-Crossover Subjects

16 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. Relationship Between Office SBP Changes and Number of Ablations Attempted for Combined* RDN Subjects at 6 Months *Denervation and crossover subjects combined

17 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. Relationship Between 24-Hr Ambulatory SBP Changes and Number of Ablations Attempted for Combined* RDN Subjects at 6 Months *Denervation and crossover subjects combined

18 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. Systolic Blood Pressure Change at 6 Months According to Ablation Pattern Four quadrants = 1 superior, 1 inferior, and 2 posterior

19 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. Limitations All patients and clinicians were un-blinded at 6 months. Disposition of the original sham control group patients after 6 months was determined by eligibility and patient choice and not randomized. Most non-crossover patients had controlled office blood pressure at 6 months and thus were not eligible for crossover.

20 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14. Conclusions Renal denervation with the Symplicity™ system was safe with no difference in major adverse events between the treated and original sham procedure groups out to 12 months post procedure. Patients in the original therapy group, patients who crossed over at 6 months, and patients who did not cross over all show consistent reductions in office and ambulatory blood pressure 12 months post randomization. Possible confounding factors including the population studied, drug prescription changes, variable adherence to therapy and procedural variability all remain unresolved at 12 months. Thus, further research is needed.

21 Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by regulatory authorities in your geography. CAUTION: The Symplicity Renal Denervation System is an investigational device in the United States, limited by Federal (or United States) law to investigational use. Not for distribution in the USA, Japan or France.© 2014 Medtronic, Inc. All rights reserved. UC201502457aML 9/14.

Download ppt "Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by."

Similar presentations

RENAL SYMPATHETIC DENERVATION Anxiolytic for nervous kidneys???

RENAL SYMPATHETIC DENERVATION Anxiolytic for nervous kidneys???
For OMA distribution only. Trademarks may be registered and are the property of their respective owners © 2015 Medtronic, Inc. All Rights Reserved. 10188271DOC_1A.

For OMA distribution only. Trademarks may be registered and are the property of their respective owners © 2015 Medtronic, Inc. All Rights Reserved DOC_1A.
TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345:1291-7. Incidence of CV events in women.

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.

Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.
Overcoming the challenge of blood pressure control in prediabetic and diabetic patients: PICASSO T2D Study Efficacy and tolerability of fixed dose combination.

Overcoming the challenge of blood pressure control in prediabetic and diabetic patients: PICASSO T2D Study Efficacy and tolerability of fixed dose combination.
Renal artery denervation for treatment of patients with obstructive sleep apnea and resistant hypertension: Results from the Global SYMPLICITY Registry.

Renal artery denervation for treatment of patients with obstructive sleep apnea and resistant hypertension: Results from the Global SYMPLICITY Registry.
The safety and long-term effect of renal artery denervation on blood pressure and renal function in real world patients with uncontrolled hypertension.

The safety and long-term effect of renal artery denervation on blood pressure and renal function in real world patients with uncontrolled hypertension.
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,

Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,
Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.

Uncontrolled Hypertension, Systolic and Diastolic Blood Pressure and Development of Symptomatic Peripheral Arterial Disease in the Women’s Health Study.
Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.

Management of Hypertension according to JNC 7 BY SANDAR KYI, MD.
OVBIAGELE B, DIENER H-C, YUSUF S, ET AL., PROFESS INVESTIGATORS. LEVEL OF SYSTOLIC BLOOD PRESSURE WITHIN THE NORMAL RANGE AND RISK OF RECURRENT STROKE.

OVBIAGELE B, DIENER H-C, YUSUF S, ET AL., PROFESS INVESTIGATORS. LEVEL OF SYSTOLIC BLOOD PRESSURE WITHIN THE NORMAL RANGE AND RISK OF RECURRENT STROKE.
BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.

BEAUTI f UL: morBidity-mortality EvAlUaTion of the I f inhibitor ivabradine in patients with coronary disease and left ventricULar dysfunction Purpose.
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.

Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
Trademarks may be registered and are the property of their respective owners. A reminder that this is a discussion of SYMPLICITY trial results and their.

Trademarks may be registered and are the property of their respective owners. A reminder that this is a discussion of SYMPLICITY trial results and their.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.

The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.

Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.

0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
ONTARGET Risk factors and outcomes associated with nonadherence Background ONTARGET compared the efficacy of the ARB telmisartan, the ACE inhibitor ramipril,

ONTARGET Risk factors and outcomes associated with nonadherence Background ONTARGET compared the efficacy of the ARB telmisartan, the ACE inhibitor ramipril,
10/5/2015. Hypertension GuidelinesDate JNC JNC 72003 JNC 82013 NICE Guidelines 2011 ESC / ESH Hypertension Guidelines ESC Guideline2007.

10/5/2015. Hypertension GuidelinesDate JNC JNC JNC NICE Guidelines 2011 ESC / ESH Hypertension Guidelines ESC Guideline2007.
Combination Therapy for Hypertension Summary and Comment by Harlan M. Krumholz, MD, SM Published in Journal Watch Cardiology December 3, 2008Journal Watch.

Combination Therapy for Hypertension Summary and Comment by Harlan M. Krumholz, MD, SM Published in Journal Watch Cardiology December 3, 2008Journal Watch.

Similar presentations

Ads by Google